Talk:Angela Hartley Brodie
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
 | A fact from Angela Hartley Brodie appeared on Wikipedia's Main Page in the Did you know column on 19 February 2016 (check views). The text of the entry was as follows:
|  |
A list of information about her works to be included in article..
editHello all,
Me and User: Worm That Turned have tried our best with this article though we have a very limited knowledge of medical research. I am hoping to enlist assistance from very helpful editors at the Medical Project!
- 1973 published initial studies on Aromatase Inhibitors[1]
- 1982 tested inhibitors - England collaboration[2]
- Cancer treatment - Aromatase inhibitors[3]
- Developed Formestane first aromatase inhibitor to be used on breast cancer patients 1994 was first marketed
- Now developing steroidal compounds to stop reoccurring cancers.[4]
- Working on Prostate cancer.[4]
- History of her early works with husband[5]
- 200 papers in journals.[3]
- "She has served on many NIH and NCI study sections as well as being a reviewer and . She is also a member of the Advisory Board for the Komen Foundation."[6]
- 2014 report about her current work.[7]
- She was an ad-hoc member of the integration panel for the U.S. Army department of Defense Army breast cancer research program[8]
Thanks, ツStacey (talk) 17:53, 25 January 2016 (UTC)
- ^ Stockwell, Brent (15 January 2013). "The Vanishing Cures". The Quest for the Cure: The Science and Stories Behind the Next Generation of Medicines (illustrated ed.). Columbia University Press. p. 62. ISBN 9780231152136. Retrieved 22 January 2016.
- ^ Cite error: The named reference
Psychewas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
UMMCwas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Nasswas invoked but never defined (see the help page). - ^ Santen, R. J.; Brodie, H.; Simpson, E. R.; Siiteri P. K.; Brodie, A. (1 July 2013). "History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target". Endocrine Reviews. 30 (4). ISSN 1945-7189. Retrieved 23 January 2016.
- ^ Cite error: The named reference
ASPETwas invoked but never defined (see the help page). - ^ Rooney, Rita M. (2012). "Aromatase Inhibitors" (PDF). Medical Bulletin. 97 (2). University of Maryland: 8–11. Retrieved 24 January 2016.
- ^ "FY99 CDMRP Annual Report: FY99 Ad Hoc Integration Panel Members". Department of Defence - Congressionally directed medical research programs. Retrieved 24 January 2016.
Timeline
editA source says
Angela Brodie continued research at the Worcester Foundation for eighteen years, developing aromatase inhibitors and showing their clinical efficacy in model systems. Harry Brodie took a different path, leaving laboratory research in 1978 and becoming an administrator at the NIH.
It was eagerness to initiate clinical trials of aromatase inhibitors that brought Angela Brodie to the University of Maryland in 1979.
Of course working backwards from 1979 gives 1961 as her arrival time. However I am pretty sure another source has her arriving in 1963.
All the best: Rich Farmbrough, 19:25, 21 February 2016 (UTC).
- Indeed, according to History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target she arrived in 1962. All the best: Rich Farmbrough, 19:38, 21 February 2016 (UTC).
Context
editWe should place the aromatase inhibitors work in the context of the following:
As a result of his ongoing mechanistic studies, Harry Brodie recognized the therapeutic potential of targeting aromatase and began development of selective aromatase inhibitors in the early 1970s. In 1973, his group published initial systematic studies on the development of competitive steroidal aromatase inhibitors (17). Although a number of classical inhibitors that blocked multiple cytochrome P450 hydroxylases had previously proved useful for mechanistic studies (i.e., cyanoketone p-hydroxymercuribenzoate and AG) (34, 35), none of these compounds was specific for aromatase (35, 40). The WFEB group reasoned that steroidal analogs of aromatase substrates would be more specific inhibitors, resulting from their high-affinity interactions with the active site of the enzyme. Brodie’s group systematically examined more than 100 steroidal structures and substrate analogs (17) and inferred important structural components for inhibition from these data.
History of.... etc.
All the best: Rich Farmbrough, 19:52, 21 February 2016 (UTC).
- Sadly the references in that document appear to be broken. All the best: Rich Farmbrough, 19:54, 21 February 2016 (UTC).
- http://press.endocrine.org/doi/abs/10.1210/endo-92-3-866 Possibly the first publication on aromatase inhibitors?
- http://press.endocrine.org/doi/abs/10.1210/endo-100-6-1684 Results on reproductive supression and neoplasms (in rats).